Carl Juneau, MD
Interventional Cardiology · Sparks, NVNPI 1376560276
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,764 of the $11,176 with a category attached, or 69.5%. 28 manufacturers reported payments, led by Abbott at 35.2% of the total. Reporting peaked in 2019 at $3,979 and has fallen 91.9% since, to $323 in 2025.
Across 237 payments — averaging $47.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Boston Scientific$2K
- Medtronic$1K
- Abiomed$596
- Shockwave Medical, Inc$546
- Johnson & Johnson$478
- plus $2K from 22 others
What the payments were for
- Travel & lodging$3,38230%
- Food & beverage$7,76469%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 38 | $3,932 |
| Boston Scientific | 53 | $1,982 |
| Medtronic(2 entities) | 14 | $1,360 |
| Abiomed | 10 | $596 |
| Shockwave Medical, Inc | 5 | $546 |
| Johnson & Johnson | 25 | $478 |
| Amarin Pharma, Inc. | 14 | $254 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $253 |
| Acist Medical Systems, Inc. | 3 | $252 |
| AstraZeneca | 13 | $247 |
| Biotronik Inc. | 5 | $231 |
| Novartis | 8 | $173 |
| Pfizer | 8 | $141 |
| Irhythm Technologies, Inc. | 5 | $120 |
| Inspire Medical Systems, Inc. | 1 | $105 |
| Amgen | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 5 | $86 |
| Merck | 3 | $62 |
| Penumbra, Inc. | 2 | $51 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $36 |
| Cook Medical LLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| United Therapeutics Corporation | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $16 |
| Teleflex LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,709
- Micra$1,104
- OPTIS$592
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$323
- RESONATE EL ICD VR$273
- HD-IVUS$186
- WATCHMAN FLX$121
- AMPLATZER Occluders$119
- Impella$116
- NC TREK coronary catheters$116
- CARDIOMEMS$112
- Vascepa$109
- Inspire$105
How this compares
$11,176 in reported general payments places this provider in the 55th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 244 | $244,110 |
| EntrestoSacubitril/Valsartan | 123 | $132,493 |
| XareltoRivaroxaban | 56 | $68,307 |
| BrilintaTicagrelor | 42 | $31,341 |
| JardianceEmpagliflozin | 32 | $25,975 |
| Praluent PenAlirocumab | 46 | $25,799 |
| Repatha SureclickEvolocumab | 20 | $19,716 |
| VascepaIcosapent Ethyl | 12 | $5,191 |
| SotalolSotalol Hcl | 78 | $4,159 |
| Rosuvastatin Calcium | 107 | $3,809 |
| Sildenafil Citrate | 17 | $2,946 |
| Atorvastatin Calcium | 79 | $2,561 |
| Amiodarone Hcl | 71 | $2,204 |
| Digoxin | 80 | $1,997 |
| ClopidogrelClopidogrel Bisulfate | 90 | $1,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $141 | $244,110244 claims |
| NovartisEntresto | $173 | $132,493123 claims |
| Johnson & JohnsonXarelto | $478 | $68,30756 claims |
| AstraZenecaBrilinta | $247 | $31,34142 claims |
| Boehringer IngelheimJardiance | $36 | $25,97532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Sparks
- Ali Al KhayruSparks$11K
- Eric DrummerSparks$9K
- Thomas TruongSparks$8K
- Cres MirandaLas Vegas$660K
- Jeffrey LevismanHenderson$226K
- Howard BroderHenderson$168K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Karthiek NaralaHenderson$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.